Journal of Shanghai Jiao Tong University (Medical Science) >

2023 , Vol. 43 >Issue 5: 580 - 591

DOI: https://doi.org/10.3969/j.issn.1674-8115.2023.05.008

Basic research

Effect of montelukast on leukotriene B4 metabolism in asthma

  • Yu HU ,
  • Liang XIE ,
  • Dan ZOU ,
  • Hongling FU ,
  • Lili LOU ,
  • Keqi XIE ,
  • Hanmin LIU
Expand
  • 1.Department of Pediatric Pulmonology and Immunology, West China Second University Hospital, Sichuan University, Chengdu, 610041, China
    2.The Joint Laboratory for Lung Development and Related Diseases of West China Second University Hospital, Sichuan University and School of Life Sciences of Fudan University; West China Institute of Women and Children′s Health, West China Second University Hospital, Sichuan University, Chengdu, 610041, China
    3.Department of Pediatrics, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, 621000, China
    4.Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, 610041, China
    5.NHC Key Laboratory of Chronobiology (Sichuan University), Chengdu, 610041, China
LIU Hanmin, E-mail: liuhm@scu.edu.cn.

Received date: 2023-03-31

  Accepted date: 2023-01-03

  Online published: 2023-07-11

Supported by

National Natural Science Foundation of China-Joint Fund for Regional Innovation and Development(U21A20333);Central Government Funds of Guiding Local Scientific and Technological Development for Sichuan Province(2021ZYD0105);Fundamental Research Funds for the Central Universities(SCU2022D022);Popularization and application project of Sichuan Health Committee(20PJ254)

Fold

Abstract

Objective ·To observe the effect of montelukast on the expressions of key genes in LTB4 (leukotriene B4) metabolic pathway in treating asthma and investigate the candidate intervene targets of asthma. Methods ·The acute, subacute, and chronic asthmatic mouse models characterizing by allergic airway disease (AAD) were set up by ovalbumin (OVA) and Al(OH)3 sensitization and challenge and intervened by intragastric administration of montelukast and finally challenged by OVA for chronic asthma model. The pulmonary functions of mice were tested by unconstrained whole body plethysmograph, to quest the change patterns of airway hyperresponsiveness (AHR). The eosinophil (EOS) infiltration and goblet cell (GCL) hyperplasia in mouse lungs were detected by hematoxylin-eosin (HE) staining, to quest the pathologic features of airway allergic inflammation. The levels of immunoglobulin E (IgE), interferon γ (IFN-γ), and interleukin (IL) in bronchoalveolar lavage fluid (BALF) and serum were detected by ELISA and Milliplex kits, to quest the helper T cell type 2 (Th2) inflammation status. The transcription and protein levels of 5-lipoxygenase activating protein (ALOX5AP), leukotriene A4 hydrolase (LTA4H), and leukotriene B4 receptor 1 (BLT1) genes, which encoded the rate-limiting enzymes in LTB4 synthesis pathway, were detected by RT-qPCR, Western blotting and immunohistochemistry (IHC). Results ·The asthmatic mouse model could be set up by OVA and Al (OH)3 and was presented as AHR characterized by increasing enhanced pause (Penh) value, eosinophilic inflammation and high mucous secretion pathologically characterized by airway EOS infiltration and GCL hyperplasia, Th2 inflammation immunologically characterized by the increasing levels of IgE, IL-4, and IL-13 as well as decreasing levels of IFN-γ, IL-2, and IL-12 in BALF and serum. Montelukast could alleviate AAD effectively. The transcription and protein levels of ALOX5AP, LTA4H, and BLT1 genes increased in asthma. Montelukast can inhibit the expression of ALOX5AP gene and promote the expressions of LTB4 and BLT1 genes in asthmatic chronic phase. When challenged by OVA once again, montelukast can induce the significantly high expressions of LTB4 and BLT1 genes. Conclusion ·Montelukast has the effect of relieving allergic inflammation in asthma mice, but it can stimulate the production and accumulation of LTB4 and is significant in chronic phase. When challenged by OVA a second time, LTB4 could be promoted to combine with BLT1 and attend in the pathogenesis of asthma. The results suggested that there was a potential risk of activation of LTB4 by montelukast. The rate-limiting enzyme LTA4H and its receptor BLT1 metabolism may be potential targets for asthma treatment.

Key words： asthma; 5-lipoxygenase activating protein (ALOX5AP); leukotriene A4 hydrolase (LTA4H); leukotriene B4 receptor; montelukast

Cite this article

Yu HU , Liang XIE , Dan ZOU , Hongling FU , Lili LOU , Keqi XIE , Hanmin LIU . Effect of montelukast on leukotriene B4 metabolism in asthma[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023 , 43(5) : 580 -591 . DOI: 10.3969/j.issn.1674-8115.2023.05.008

References

1 JOHNSON C C, CHANDRAN A, HAVSTAD S, et al. US childhood asthma incidence rate patterns from the ECHO consortium to identify high-risk groups for primary prevention[J]. JAMA Pediatr, 2021, 175(9): 919-927.
2 MESHRAM D, BHARDWAJ K, RATHOD C, et al. The role of leukotrienes inhibitors in the management of chronic inflammatory diseases[J]. Recent Pat Inflamm Allergy Drug Discov, 2020, 14(1): 15-31.
3 YAMAMOTO T, MIYATA J, ARITA M, et al. Current state and future prospect of the therapeutic strategy targeting cysteinyl leukotriene metabolism in asthma[J]. Respir Investig, 2019, 57(6): 534-543.
4 NIALS A T, UDDIN S. Mouse models of allergic asthma: acute and chronic allergen challenge[J]. Dis Model Mech, 2008, 1(4/5): 213-220.
5 LOCKE N R, ROYCE S G, WAINEWRIGHT J S, et al. Comparison of airway remodeling in acute, subacute, and chronic models of allergic airways disease[J]. Am J Respir Cell Mol Biol, 2007, 36(5): 625-632.
6 PADRID P, SNOOK S, FINUCANE T, et al. Persistent airway hyperresponsiveness and histologic alterations after chronic antigen challenge in cats[J]. Am J Respir Crit Care Med, 1995, 151(1): 184-193.
7 CHO K S, PARK M K, KANG S A, et al. Adipose-derived stem cells ameliorate allergic airway inflammation by inducing regulatory T cells in a mouse model of asthma[J]. Mediators Inflamm, 2014, 2014: 436476.
8 MIYATA J, FUKUNAGA K, KAWASHIMA Y, et al. Cysteinyl leukotriene metabolism of human eosinophils in allergic disease[J]. Allergol Int, 2020, 69(1): 28-34.
9 BRUNO F, SPAZIANO G, LIPARULO A, et al. Recent advances in the search for novel 5-lipoxygenase inhibitors for the treatment of asthma[J]. Eur J Med Chem, 2018, 153: 65-72.
10 LECHNER A, HENKEL F D R, HARTUNG F, et al. Macrophages acquire a TNF-dependent inflammatory memory in allergic asthma[J]. J Allergy Clin Immunol, 2022, 149(6): 2078-2090.
11 RO M, LEE A J, KIM J H. 5-/ 12-Lipoxygenase-linked cascade contributes to the IL-33-induced synthesis of IL-13 in mast cells, thus promoting asthma development[J]. Allergy, 2018, 73(2): 350-360.
12 DOHERTY T A, KHORRAM N, LUND S, et al. Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production[J]. J Allergy Clin Immunol, 2013, 132(1): 205-213.
13 THIVIERGE M, STANKOVá J, ROLA-PLESZCZYNSKI M. IL-13 and IL-4 up-regulate cysteinyl leukotriene 1 receptor expression in human monocytes and macrophages[J]. J Immunol, 2001, 167(5): 2855-2860.
14 ZHOU X J, QIN Z, LU J, et al. Efficacy and safety of salmeterol/fluticasone compared with montelukast alone (or add-on therapy to fluticasone) in the treatment of bronchial asthma in children and adolescents: a systematic review and meta-analysis[J]. Chin Med J, 2021, 134(24): 2954-2961.
15 DEBELLEIX S, SIAO-HIM FA V, BEGUERET H, et al. Montelukast reverses airway remodeling in actively sensitized young mice[J]. Pediatr Pulmonol, 2018, 53(6): 701-709.
16 WANG W L, LUO X M, ZHANG Q, et al. Bifidobacterium infantis relieves allergic asthma in mice by regulating Th1/Th2[J]. Med Sci Monit, 2020, 26: e920583.
17 SUN W, LIU H Y. Montelukast and budesonide for childhood cough variant asthma[J]. J Coll Physicians Surg Pak, 2019, 29(4): 345-348.
18 ELIEH ALI KOMI D, BJERMER L. Mast cell-mediated orchestration of the immune responses in human allergic asthma: current insights[J]. Clin Rev Allergy Immunol, 2019, 56(2): 234-247.
19 BRIGHTLING C E, BRUSSELLE G, ALTMAN P. The impact of the prostaglandin D2 receptor 2 and its downstream effects on the pathophysiology of asthma[J]. Allergy, 2020, 75(4): 761-768.
20 SCHEXNAYDRE E E, GERSTMEIER J, GARSCHA U, et al. A 5?lipoxygenase-specific sequence motif impedes enzyme activity and confers dependence on a partner protein[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2019, 1864(4): 543-551.
21 MU?OZ N M, MELITON A Y, MELITON L N, et al. Secretory group V phospholipase A2 regulates acute lung injury and neutrophilic inflammation caused by LPS in mice[J]. Am J Physiol Lung Cell Mol Physiol, 2009, 296(6): L879-L887.
22 LESLIE C C. Cytosolic phospholipase A?: physiological function and role in disease[J]. J Lipid Res, 2015, 56(8): 1386-1402.
23 SOKOLOWSKA M, STEFANSKA J, WODZ-NASKIEWICZ K, et al. Cytosolic phospholipase A2 group IVA is overexpressed in patients with persistent asthma and regulated by the promoter microsatellites[J]. J Allergy Clin Immunol, 2010, 125(6): 1393-1395.
24 GRANATA F, STAIANO R I, LOFFREDO S, et al. The role of mast cell-derived secreted phospholipases A2 in respiratory allergy[J]. Biochimie, 2010, 92(6): 588-593.
25 TOUQUI L. Antisense inhibition of phospholipase A2: a new approach for already tested therapeutic targets for the treatment of sepsis[J]. Crit Care Med, 2012, 40(7): 2250-2251.
26 ZAMAN K, HANIGAN M H, SMITH A, et al. Endogenous S-nitrosoglutathione modifies 5-lipoxygenase expression in airway epithelial cells[J]. Am J Respir Cell Mol Biol, 2006, 34(4): 387-393.
27 KOGA T, SASAKI F, SAEKI K, et al. Expression of leukotriene B4 receptor 1 defines functionally distinct DCs that control allergic skin inflammation[J]. Cell Mol Immunol, 2021, 18(6): 1437-1449.
28 PAL K, FENG X, STEINKE J W, et al. Leukotriene A4 hydrolase activation and leukotriene B4 production by eosinophils in severe asthma[J]. Am J Respir Cell Mol Biol, 2019, 60(4): 413-419.
29 HE R, CHEN Y, CAI Q. The role of the LTB4-BLT1 axis in health and disease[J]. Pharmacol Res, 2020, 158: 104857.
30 UCHIDA Y, SOMA T, NAKAGOME K, et al. Implications of prostaglandin D2 and leukotrienes in exhaled breath condensates of asthma[J]. Ann Allergy Asthma Immunol, 2019, 123(1): 81-88.e1.
31 PREEZ S D, RAIDAL S L, DORAN G S, et al. Exhaled breath condensate hydrogen peroxide, pH and leukotriene B4 are associated with lower airway inflammation and airway cytology in the horse[J]. Equine Vet J, 2019, 51(1): 24-32.
32 STAPLETON R D, SURATT B T, NEFF M J, et al. Bronchoalveolar fluid and plasma inflammatory biomarkers in contemporary ARDS patients[J]. Biomarkers, 2019, 24(4): 352-359.
33 BERRY K A, BORGEAT P, GOSSELIN J, et al. Urinary metabolites of leukotriene B4 in the human subject[J]. J Biol Chem, 2003, 278(27): 24449-24460.
34 LEE J J, DIMINA D, MACIAS M P, et al. Defining a link with asthma in mice congenitally deficient in eosinophils[J]. Science, 2004, 305(5691): 1773-1776.
35 ASANUMA F, KUWABARA K, ARIMURA A, et al. Effects of leukotriene B4 receptor antagonist, LY293111Na, on antigen-induced bronchial hyperresponsiveness and leukocyte infiltration in sensitized guinea pigs[J]. Inflamm Res, 2001, 50(3): 136-141.
36 KUBO M. Mast cells and basophils in allergic inflammation[J]. Curr Opin Immunol, 2018, 54: 74-79.
37 LEE Y J, KIM C K. Montelukast use over the past 20 years: monitoring of its effects and safety issues[J]. Clin Exp Pediatr, 2020, 63(10): 376-381.
Options
Outlines

/

〈 〉